Thanks for your question. We will answer you soon.
Treatment with Adalimumab (HUMIRA) for Rheumatoid Arthritis (RA)
Daniel Furst, MD
University of California, Los Angeles, Los Angeles, CA

Date Added: 06/26/13

Adalimumab or Humira, in the United States, is biologic and a DMARD, in fact, all biologic are DMARDs. A DMARD is a disease-modifying antirheumatic drug. So there are a number of biologics. Among those are a group called tumor necrosis factor inhibitors, and adalimumab is an antibody. That means...
---------------------------------------------------------- ----------------------------------------------------------
Dr. Daniel Furst is the first Carl M Pearson Professor in Rheumatology. He has been on a number of national committees concerned with rheumatic therapeutics, including as a member and Fellow in the American College of Rheumatology and The American Society of Clinical Pharmacology and Therapeutics. He has also been a member of the Arthritis Advisory Committee for the FDA. He currently serves as Chairman of the Innovative Therapies Meeting of the American College of Rheumatology and Clinical Abstracts Selection Chair for the National American College of Rheumatology meeting and Chairman of the Standing Committee on Clinical Trials for the International League Against Rheumatism. Dr. Furst has published more than 400 articles and 12 books, including more than 180 research articles and more than 210 reviews or chapters in addition to two editions of a book on scleroderma. Dr. Furst's areas of research interest include RA, scleroderma and polymyosistis/dermatomyositis.
Have Additional Questions About RA?
Get answers from our physicians
Thank you for your question, and for helping us make this RA Community more robust and helpful to patients like yourself. We'll be in touch soon.